retatrutide triple agonist obesity trial Today, we shared new data from two Phase 3 trials of retatrutide, our investigational agonist. Learn more: https://go.lilly.com/msrz1v 🚨 HOT OFF THE PRESS:

They have emerged as key therapeutic targets in diabetes and obesity research, inspiring the development of dual and triple receptor agonists that synergistically enhance glycemic control, promote weight loss, and improve overall metabolic health [3]

Without it, the GLP-1 and glucagon combination would produce significantly worse nausea and gastrointestinal symptoms

The gentle approach prevents damaging the peptide structure and promotes even dissolution

Understanding how GLP-1 medications work in the body helps put orforglipron unique profile in context

Retatrutide progressed through early-phase clinical trials, showing strong potential for both glycemic control and weight reduction

Some users report fatigue and changes in appetite